Processing

Please wait...

Settings

Settings

Goto Application

1. WO2021144020 - ANTIGEN BINDING PROTEINS SPECIFICALLY BINDING PRAME

Publication Number WO/2021/144020
Publication Date 22.07.2021
International Application No. PCT/EP2020/050936
International Filing Date 15.01.2020
IPC
A61K 39/395 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
C07K 14/47 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
46from vertebrates
47from mammals
C07K 14/725 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
725T-cell receptors
C07K 16/30 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
30from tumour cells
CPC
A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies
C07K 14/4748
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
46from vertebrates
47from mammals
4701not used
4748Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
C07K 14/7051
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
70503Immunoglobulin superfamily
7051T-cell receptor (TcR)-CD3 complex
C07K 16/3053
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
30from tumour cells
3053Skin, nerves, brain
C07K 2317/34
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
30characterized by aspects of specificity or valency
34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
C07K 2317/73
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
70characterized by effect upon binding to a cell or to an antigen
73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Applicants
  • IMMATICS BIOTECHNOLOGIES GMBH [DE]/[DE]
Inventors
  • BUNK, Sebastian
  • HOFMANN, Martin
  • HUTT, Meike
  • MAURER, Dominik
  • PSZOLLA, Gabriele
  • SCHWÖBEL, Frank
  • UNVERDORBEN, Felix
  • WAGNER, Claudia
  • YOUSEF, Sara
Agents
  • BÖHMER, Thomas
Priority Data
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) ANTIGEN BINDING PROTEINS SPECIFICALLY BINDING PRAME
(FR) PROTÉINES DE LIAISON À L'ANTIGÈNE SE LIANT DE MANIÈRE SPÉCIFIQUE À PRAME
Abstract
(EN)
The present invention concerns antigen binding proteins directed against FRAME protein- derived antigens. The invention in particular provides antigen binding proteins which are selective and specific for the tumor expressed antigen FRAME, wherein the tumor antigen comprises or consists of SEQ ID NO: 8 and is in a complex with a major histocompatibility complex (MHC) protein. The antigen binding proteins of the invention contain, in particular, the complementary determining regions (CDRs) of novel engineered T cell receptors (TCRs) that specifically bind to said FRAME peptide. The antigen binding proteins of the invention are for use in the diagnosis, treatment and prevention of FRAME expressing cancerous diseases. Further provided are nucleic acids encoding the antigen binding proteins of the invention, vectors comprising said nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins of the invention.
(FR)
La présente invention concerne des protéines de liaison à l'antigène dirigées contre des antigènes dérivés de protéine FRAME. L'invention concerne en particulier des protéines de liaison à l'antigène qui sont sélectives et spécifiques pour l'antigène FRAME exprimé sur une tumeur, l'antigène tumoral comprenant ou étant constitué de SEQ ID NO : 8 et est dans un complexe avec une protéine du complexe majeur d'histocompatibilité (CMH). Les protéines de liaison à l'antigène selon l'invention contiennent, en particulier, des régions déterminant la complémentarité (CDR) de nouveaux récepteurs de lymphocytes T modifiés (TCR) qui se lient de manière spécifique audit peptide FRAME. Les protéines de liaison à l'antigène selon l'invention sont utiles pour le diagnostic, le traitement et la prévention de maladies cancéreuses exprimant FRAME. L'invention concerne, en outre, des acides nucléiques codant pour les protéines de liaison à l'antigène selon l'invention, des vecteurs comprenant lesdits acides nucléiques, des cellules de recombinaison exprimant les protéines de liaison à l'antigène et des compositions pharmaceutiques comprenant les protéines de liaison à l'antigène selon l'invention.
Latest bibliographic data on file with the International Bureau